ACUDIN: ACUpuncture and laser acupuncture for treatment of DIabetic peripheral Neuropathy: a randomized, placebo-controlled, partially double-blinded trial

Meyer-Hamme et al. · BMC Neurology · 2018

🔬Three-Arm RCT Protocol👥n=180 participants📊High methodological rigor

Evidence Level

MODERATE
75/ 100
Quality
4/5
Sample
4/5
Replication
3/5
🎯

OBJECTIVE

To investigate whether needle acupuncture and laser acupuncture improve electrophysiological parameters in diabetic peripheral neuropathy

👥

WHO

180 patients with type 2 diabetes and confirmed diabetic peripheral neuropathy

⏱️

DURATION

10 sessions over 10 weeks, with follow-up up to 15 weeks

📍

POINTS

Bafeng (Ex-LE-10), Qiduan (Ex-LE-12) and Lianqiu (ST-34), bilaterally

🔬 Study Design

180participants
randomization

Needle Acupuncture

n=60

Traditional needle acupuncture at points on feet and legs

Real Laser Acupuncture

n=60

Multichannel red laser at the same points

Placebo Laser Acupuncture

n=60

Identical procedure but without laser emission

⏱️ Duration: 10 weeks of treatment + 5 weeks of follow-up

📊 Results in numbers

SNAP amplitude of the sural nerve

Primary outcome

0%

Statistical power

0.05

Alpha

1 μV

Expected difference

Percentage highlights

80%
Statistical power

📊 Outcome Comparison

Expected SNAP Amplitude

Minimum detectable difference
1
💬 What does this mean for you?

This study will test whether traditional needle acupuncture or laser acupuncture can improve nerve function in people with diabetes who have developed numbness and pain in their feet. The researchers will objectively measure nerve function through special nerve conduction tests, in addition to symptoms reported by patients.

📝

Article summary

Plain-language narrative summary

Diabetic peripheral neuropathy represents the most common complication of diabetes mellitus, significantly affecting patients' quality of life. This condition manifests through damage to the nerves caused by excess blood sugar and other metabolic factors, resulting in symptoms such as numbness, pain, tingling, and muscle weakness, especially in the feet and legs. The problem follows a characteristic pattern, beginning in the toes and progressing toward the legs, as if the patient were wearing a stocking. Unfortunately, conventional treatment options are limited, focusing mainly on pain control through anticonvulsant or antidepressant medications, but leaving an important gap in the treatment of sensory loss and balance problems that can lead to falls and fractures.

The ACUDIN study was developed to investigate whether traditional needle acupuncture and laser acupuncture can offer therapeutic benefits for patients with diabetic peripheral neuropathy. It is a randomized, placebo-controlled, partially double-blinded clinical trial, conducted in Germany by the Hanse Merkur Center for Traditional Chinese Medicine at the University of Hamburg-Eppendorf. The study was designed to include 180 patients with type 2 diabetes and confirmed peripheral neuropathy, divided equally into three groups: traditional needle acupuncture, real laser acupuncture, and placebo laser acupuncture. The treatment protocol consists of 10 sessions over 10 weeks, with each session lasting 20 minutes, using specific acupuncture points on the feet and legs.

The study methodology was carefully developed to overcome the traditional challenges of acupuncture research, particularly the difficulty of creating an adequate control group. For needle acupuncture, a single-blind design was implemented, as it is impossible to completely mask the procedure from the acupuncturist. For laser acupuncture, a true double-blind design was established, where neither the patient nor the acupuncturist knows whether the laser is actually working. This was made possible through an elaborate protocol involving two study nurses and the use of laser safety goggles, which prevent patients from perceiving whether the equipment is active.

The researchers chose a specific combination of 20 acupuncture points on the feet and legs, based on previous pilot studies that showed promising results. The primary outcome of the study is measured through nerve conduction studies, objective examinations that evaluate nerve function through the measurement of the velocity and amplitude of electrical impulses.

The preliminary results and pilot studies that preceded this trial showed encouraging evidence that acupuncture can improve both objective parameters of nerve function and patients' subjective symptoms. Nerve conduction studies revealed improvements in the transmission of electrical impulses through the nerves after treatment with acupuncture, suggesting possible neural regeneration or improvement of existing nerve function. In parallel, patients reported reduction in neuropathic pain, decrease in tingling, and improvement in sensation and balance. These findings are particularly significant because acupuncture has demonstrated benefits in areas where conventional treatments are ineffective, especially in the improvement of reduced sensation and balance problems.

The proposed mechanism for these benefits includes increased blood flow to peripheral nerves through the small vessels that supply them, potentially facilitating neural repair and regeneration.

The clinical implications of this study are substantial for both patients and health care professionals. For patients, acupuncture may represent a safe and effective complementary therapeutic option that addresses aspects of diabetic peripheral neuropathy that are not adequately treated by conventional medications. This is particularly relevant considering that many patients experience side effects from neuropathic pain medications or do not respond adequately to these treatments. Acupuncture offers a non-pharmacological approach that can improve quality of life without the risks associated with long-term medication use.

For health care professionals, this study may provide robust scientific evidence to incorporate acupuncture as part of an integrated treatment plan for diabetic peripheral neuropathy. In addition, acupuncture may represent a more cost-effective treatment option compared with long-term pharmacological therapies, potentially reducing the health care costs associated with diabetic neuropathy complications.

The study presents some important limitations that should be considered when interpreting the results. The impossibility of implementing a completely double-blind design for needle acupuncture introduces a potential bias, although the researchers minimized this through the use of independent assessors who are unaware of the type of treatment received. In addition, the study focuses specifically on patients with type 2 diabetes, limiting the generalizability of the results to other types of peripheral neuropathy. The duration of follow-up is also relatively short, and long-term studies will be needed to determine whether the benefits of acupuncture are maintained over time.

Another consideration is that the efficacy of acupuncture may vary depending on the skill and experience of the acupuncturist, although the researchers standardized the training and qualification of the professionals involved in the study.

This clinical trial represents a significant advance in research on acupuncture for diabetic peripheral neuropathy, using rigorous methodology and objective outcomes to evaluate therapeutic efficacy. The results of this study may contribute to establishing evidence-based guidelines for the use of acupuncture in the treatment of this debilitating condition, offering patients and health care professionals an additional, scientifically validated therapeutic option. The incorporation of objective measures such as nerve conduction studies, in addition to clinical evaluations and symptom questionnaires, considerably strengthens the quality of the evidence generated. This study demonstrates the potential of acupuncture not only as a complementary therapy, but as an intervention that can address important gaps in the conventional treatment of diabetic peripheral neuropathy, offering hope to millions of patients suffering from this condition.

Strengths

  • 1Rigorous design with three groups including true placebo
  • 2Use of objective measures (nerve conduction studies)
  • 3Acupuncture protocol based on promising pilot studies
  • 4Double blinding for laser acupuncture
  • 5Adequate sample size with statistical power calculation
⚠️

Limitations

  • 1Single blinding only for needle acupuncture
  • 2Fixed point protocol without individualization
  • 3Possible selection bias in patients interested in acupuncture
  • 4Relatively short follow-up of 15 weeks
Dr. Marcus Yu Bin Pai

Expert Commentary

Dr. Marcus Yu Bin Pai

MD, PhD · Pain Medicine · Physical Medicine and Rehabilitation · Medical Acupuncture

Clinical Relevance

Diabetic peripheral neuropathy represents one of the most frustrating scenarios in pain and rehabilitation practice: we have gabapentinoids, duloxetine, and pregabalin for the pain dimension, but practically nothing that reverses sensory loss, imbalance, and fall risk — central factors for functionality and the prevention of amputations. The ACUDIN trial addresses this gap by testing needle acupuncture and laser acupuncture against placebo, with the primary outcome being sural SNAP amplitude, an objective and clinically relevant electromyographic measure. The three-arm model with real double blinding for the laser is methodologically solid and allows discrimination of specific versus nonspecific effects. For the physiatrist who follows type 2 diabetic patients with confirmed neuropathy and who has already exhausted or has contraindications to the pharmacological arsenal, this protocol offers a rational basis for incorporating acupuncture into the integrated therapeutic plan, especially when the objective is to improve protective sensation and postural stability.

Notable Findings

The most noteworthy aspect of ACUDIN is not just what is measured, but how it is measured: sural SNAP amplitude as the primary outcome places the discussion in the realm of neurophysiology, not just reported symptoms. This is relevant because changes in SNAP amplitude indicate real variation in the density of functioning fibers or in axonal conduction — not simply modulation of pain perception. The proposed mechanism of increased flow in the vasa nervorum is consistent with what we know about the role of endoneural ischemia in diabetic neuropathy and finds parallels in microcirculation studies with acupuncture. The true double blinding for laser acupuncture — with an elaborate protocol of two nurses and safety goggles — resolves the chronic problem of expectation contamination in physical therapy studies, making the laser arm methodologically comparable to the best pharmacological trials. The inclusion of 180 patients with power calculation to detect a 1 μV difference in SNAP reinforces that the investigators calibrated the study for clinical relevance, not just statistical significance.

From My Experience

In my practice in the pain and rehabilitation clinic, I have followed patients with diabetic neuropathy for more than two decades, and the greatest demand I hear is not 'take away my pain' — it is 'I want to feel my floor again.' This distinction completely changes therapeutic planning. I usually recommend acupuncture in these patients as an adjuvant to optimized glycemic control and physical therapy with proprioceptive training, and the response I typically observe begins to take shape between the fourth and sixth session, with perceptible improvement in plantar sensation and sleep quality. Weekly sessions in the first 10 weeks, followed by biweekly or monthly maintenance, correspond to the profile I have adopted — close to the ACUDIN protocol. The profile that responds best, in my experience, is the patient with moderate-intensity neuropathy, reasonable glycemic control, and without severe overlying peripheral vascular disease. I do not recommend acupuncture as monotherapy and do not replace the review of the antidiabetic regimen — acupuncture enters as a component of a plan that includes supervised exercise, orthotics when necessary, and, eventually, duloxetine for the pain component.

PhD in Health Sciences, University of São Paulo. Board-certified in Pain Medicine, Physical Medicine and Rehabilitation, and Medical Acupuncture.

Full original article

Read the full scientific study

BMC Neurology · 2018

DOI: 10.1186/s12883-018-1037-0

Access original article
CITED IN · 02 PAGES

Condition pages and clinical articles that cite this evidence as the basis of their recommendations.

Scientific Review

Marcus Yu Bin Pai, MD, PhD

Marcus Yu Bin Pai, MD, PhD

CRM-SP: 158074 | RQE: 65523 · 65524 · 655241

PhD in Health Sciences, University of São Paulo. Board-certified in Pain Medicine, Physical Medicine and Rehabilitation, and Medical Acupuncture. Scientific review and curation of every entry in this library.

Learn more about the author →
⚕️

Medical disclaimer: This content is for educational purposes only and does not replace consultation, diagnosis, or treatment by a qualified professional. Some information may be assisted by artificial intelligence and is subject to inaccuracies. Always consult a physician.

Content reviewed by the medical team at CEIMEC — Integrated Centre for Chinese Medicine Studies, a reference in Medical Acupuncture for over 30 years.